SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A quarterly earnings beat, raised outlook and record AI-compute backlogalongside managements emphasis on customer prepayments and contract-backed financingsparked an after-hours rebound and widespread short-squeeze chatter. Bulls see strong demand and improved financing prospects, while skeptics remain concerned about heavy debt, interest costs, capital spending and the path to sustained cash flow.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is centered on governance and national-security concerns surrounding CEO Jensen Huangs relationship with a customer suspected of ties to Chinese intelligence, with traders debating whether the investigation and China chip-export questions could threaten his leadership or the business. Others see the drop as an overreaction and are buying the dip, while looking to the upcoming earnings report for a business-focused counterpoint.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,011,579 in circulation. The last known price of Autonomi is 0.03102024 USD and is up 12.83 over the last 24 hours. It is currently trading on 15 active market(s) with $148,822.58 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Attention is heavily muddied by Anthropic IPO chatter mistakenly tagged to Aragons ANT token. The Aragon-specific discussion centers on the projects dissolution and completed token-redemption initiative, with holders unsure about conversion or exchange availability; other posts are mostly speculative trading reactions.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and conference call are driving attention, with traders debating the shift to recurring Samsung and Micron licensing revenue and the stronger balance sheet against an apparent estimates miss caused partly by amortizing Samsungs upfront fee over the agreement term. Bullish traders point to higher expected Q4 revenue, while skeptics cite lower product sales and the lack of a confirmed SK Hynix deal or Nasdaq uplisting.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs Q3 earnings report and conference call are driving immediate discussion, with traders noting an EPS beat but reacting to the share-price decline and debating whether the call offered meaningful progress. Many see the pending FCC rulemaking on the companys spectrum as the more important catalyst, while the bullish SpaceX-related thesis remains speculative and others point to regulatory delays and downside risk.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is drawing attention ahead of its quarterly report, with traders looking for revenue, guidance and commercialization updates that could set it apart from other quantum companies. Optimism about its products and technical progress is countered by concerns over weak price action and volatility alongside the broader quantum and tech sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly earnings beat and raised guidance have driven attention, with traders citing accelerating growth, improving profitability and analyst upgrades as support for the rally. The reaction is split between bulls expecting momentum to continue and skeptics focused on volatile post-earnings trading and resistance near recent levels.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos weaker-than-expected quarterly update and narrowed production outlook, amid Cigar Lake operating setbacks, are driving a sharp selloff and bearish discussion about further downside. Some traders see the decline as an opportunity, arguing that firm uranium-market fundamentals and longer-term nuclear demand remain intact.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly resultsstrong revenue and backlog growth but a wider-than-expected loss and Neutrons first launch pushed to 2027are driving the discussion. Traders are split between viewing the demand and backlog as evidence of growth and worrying about execution delays, ongoing losses, and dilution; shares have rebounded after the initial post-earnings selloff.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics new Claude workplace tools, including a spreadsheet product positioned against Excel, have raised concerns that Microsofts Office and Copilot franchises face stronger competition. Traders debate whether the threat is material or overstated given Microsofts entrenched enterprise ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of -7.35% and -66.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline

BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […]
The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Equity

BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.


Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation...

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...

BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher   - Here's Why

BioAge Labs (NASDAQ:BIOA) Shares Up 8.6% - What's Next...

Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

Wall Street Zen downgraded BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday...

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

BioAge Labs Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.</li><li>The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with related programs. &nbsp;</li><li>While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;</li></ul>Shares of BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) plunged on Friday after Novo Nordisk’s (NVO) late-stage trial setback raised concerns about biotech stocks pursuing similar approaches to treating heart disease through inflammation reduction. &nbsp;BIOA tumbled 64%, while GLUE dropped about 27%. BIOA clocked its worst day since December 2024, while GLUE booked its worst day ever.<h2 class="st-heading-2">NVO’s Trial Miss</h2>Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS. The once-monthly treatment was designed to lower the risk of heart attacks, strokes, and related deaths in patients with heart and kidney problems plus high inflammation. While the drug successfully reduced inflammation markers as expected, it showed no benefit in cutting those major heart events compared with a placebo. The study involved more than 6,300 patients.Novo said the miss will not change its 2026 profit outlook and that two other trials of the same drug will continue. NVO shares closed 9% lower on Friday.The result also raised questions about whether targeting inflammation this way can meaningfully protect the heart, pressuring companies with related programs such as BioAge and Monte Rosa. While BioAge’s BGE-102 is in mid-stage trials, MRT-8102 is in an early-stage study. &nbsp;<h2 class="st-heading-2">Wall Street Weighs In</h2>Analysts weighed in on BioAge, whose lead candidate BGE-102 targets a similar approach as ziltivekimab. Jefferies cut its price target to $21 from $62 but kept a Buy rating, saying the “outright” failure raises biological risk for a key inflammation marker as a heart-risk signal. The firm still sees potential differentiation for BGE-102, but called its profile harder to predict now.Citi noted BIOA’s greater-than-60% drop and agreed the data is a negative for BioAge’s heart-disease thesis, yet argued the size of the move “seems overdone” with the company’s enterprise value nearing zero. Citi maintains a Buy rating and $52 price target.Roth Capital’s Adam Walsh lowered his price target to $25 from $36 while keeping a Buy rating. The firm now sees lower chances that a partner will fund a heart trial for BGE-102 or that it will succeed, but its estimates for the same drug in eye disease stay the same. &nbsp;The new price targets on BIOA represent a potential upside of 132% to 475% from the stock’s Friday close.Jefferies also cut its price target on Monte Rosa (GLUE) to $25 from $40, still implying a potential upside of 51% from the last close, and kept a Buy rating. Success in the ZEUS trial would have supported Monte Rosa’s approach to residual inflammation in heart disease with its experimental drug MRT-8102, so the miss is “a setback.” The firm still sees prospects in other indications and other pipeline value drivers. &nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BIOA improved from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high levels.’Meanwhile, sentiment around GLUE stock rose from ‘neutral’ to ‘bullish,’ accompanied by a rise in retail chatter.A Stocktwits user termed the selloff on Friday as an “oversold play” and voiced hopes for a recovery in the next few days.<stembedurl>https://www.stocktwits.com/Gemini367/message/660591844</stembedurl>While <a href="https://stocktwits.com/symbol/BIOA">BIOA stock</a> has fallen 32% year-to-date, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> has gained 5%.&nbsp;Read more: <a href="https://stocktwits.com/news-articles/markets/equity/tmus-stock-slips-as-300-b-deutsche-telekom-merger-talks-reportedly-hit-a-roadblock/cZN4lirRJP6">TMUS Stock Slips As $300B Deutsche Telekom Merger Talks Reportedly Hit A Roadblock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAge Labs logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Earlier on Friday, Novo Nordisk reported that its experimental drug ziltivekimab failed a major late-stage trial called ZEUS.The result raised questions about whether targeting inflammation can meaningfully protect the heart, pressuring companies with rel

Monte Rosa Therapeutics Inc

Novo Nordisk A/S

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.74	--	--	N/A
Q3 '26	-$0.63	-$0.73	-15.02%	MISSED
Q2 '26	-$0.61	-$0.58	4.50%	BEAT
Q1 '26	-$0.64	-$0.52	18.70%	BEAT
Q4 '25	-$0.74	-$0.72	2.49%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIOA Earnings

Latest Earnings Results: Q3 '26

Historical Earnings